Brought to you by 
Royalty Pharma buys Prosidion's DPP-IV patent estate and royalty stream for $609mm
29 May 2020
Executive Summary
For $609mm in cash, Astellas Pharma Inc.’s Prosidion Ltd. (metabolic drug candidates) has sold Royalty Pharma (buys royalties on drugs and IP) the patent estate and associated royalty stream and milestones pertaining to dipeptidyl peptidase IV (DPP-IV) inhibitors for Type II diabetes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Royalty Pharma buys Prosidion's DPP-IV patent estate and royalty stream for $609mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice